Eleva Capital SAS Invests $1.29 Million in BioMarin Pharmaceutical Inc. $BMRN

Eleva Capital SAS bought a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 23,419 shares of the biotechnology company’s stock, valued at approximately $1,287,000. BioMarin Pharmaceutical makes up 0.3% of Eleva Capital SAS’s portfolio, making the stock its 18th biggest holding.

Several other institutional investors and hedge funds have also modified their holdings of BMRN. Nuveen LLC acquired a new position in shares of BioMarin Pharmaceutical in the 1st quarter worth approximately $184,475,000. AQR Capital Management LLC lifted its holdings in BioMarin Pharmaceutical by 127.9% during the 1st quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company’s stock worth $203,987,000 after buying an additional 1,642,206 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in BioMarin Pharmaceutical by 212.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock worth $112,607,000 after buying an additional 1,083,512 shares in the last quarter. Fuller & Thaler Asset Management Inc. acquired a new position in BioMarin Pharmaceutical during the 1st quarter worth $59,125,000. Finally, Robeco Institutional Asset Management B.V. lifted its holdings in BioMarin Pharmaceutical by 559.8% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 641,718 shares of the biotechnology company’s stock worth $35,275,000 after buying an additional 544,457 shares in the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Stock Performance

BMRN stock opened at $53.57 on Friday. The business’s fifty day moving average is $54.78 and its 200-day moving average is $57.07. The company has a quick ratio of 3.60, a current ratio of 4.83 and a debt-to-equity ratio of 0.10. The company has a market cap of $10.29 billion, a P/E ratio of 20.14, a price-to-earnings-growth ratio of 0.68 and a beta of 0.33. BioMarin Pharmaceutical Inc. has a twelve month low of $51.00 and a twelve month high of $73.51.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. JPMorgan Chase & Co. upped their price objective on BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Truist Financial reduced their price objective on BioMarin Pharmaceutical from $90.00 to $80.00 and set a “buy” rating on the stock in a report on Tuesday. UBS Group upped their price objective on BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. Stifel Nicolaus reduced their price objective on BioMarin Pharmaceutical from $91.00 to $73.00 and set a “buy” rating on the stock in a report on Tuesday, October 28th. Finally, Morgan Stanley reduced their price objective on BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating on the stock in a report on Tuesday, October 28th. Sixteen research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $90.70.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.